Agios Pharmaceuticals (AGIO) Stock Price, Quote & News

Company Profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pedi...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 649 8600

Website: www.agios.com

Address:

88 Sidney Street, Cambridge, United States

Dkll303 Jun. 4 at 9:59 AM

$AGIO give it up..this pos lost 66 viewers , they know the executives are losers ! ..can’t make chicken soup out of chicken’s shit !

0 · Reply

Libertarian_Pirate Jun. 2 at 3:11 PM

$AGIO a cheat sheet you can actually see lol. Let me know what you think

0 · Reply

Dkll303 Jun. 2 at 3:07 PM

$AGIO …NEVER A CEO HERE, DID THIS !! THEY ARE LEECHES ….blood suckers

0 · Reply

Libertarian_Pirate Jun. 2 at 3:06 PM

$AGIO Created a cheat sheet for EHA presentations. Hopefully you find it helpful.

0 · Reply

Dkll303 Jun. 2 at 2:05 PM

$AGIO agreed and also….THEY SUCK at building value PROS at spending money both on: Buy back at $48.50 ALNY a drug for 25 M Now this Korean joke for 17M WHAT THE FCUK DID , THESE EXECUTIVES CREATE LOWER STOCK PRICE 55% LOSSES For shareholders in 8 years !!! Such LOSERS …

0 · Reply

stu4 Jun. 1 at 7:57 PM

$AGIO Senior executives, once again LIED to shareholders on the earnings call Never mentioned buying up a potential drug Clearly their scientific staff is of a D quality, right out of college and no abilities, just lab rats !

0 · Reply

stu4 Jun. 1 at 12:20 PM

$AGIO they lack qualified scientists to create new drugs , they just abandoned a Phase 2 !!! How pathetic. So LETS GO BUY OUR PRODUCTS …25M to South Korea , since we lack the innovation with existing OVER PAID scientists of ours 25M to South Korea for a drug they developed 17 M to ALNY for another drug they developed Guess at AGIO , the develope ..WHAT ? Oh, a SELL Plan of their options !!! Quarterly , I may add . You wonder why on November 19 2025 , Bellevenue SOLD OUT to a 40 Million dollar LOSS …they cut their losses early

0 · Reply

freddie04 May. 30 at 11:06 AM

$AGIO ..oh the board , is stacked with crony buddies from Celgene …so you shareholders are fcuked !!! You’re stuck with these losers …right on Dkll303, but hopeless post

1 · Reply

Dkll303 May. 30 at 1:52 AM

$AGIO wake up , shareholders .these misfits running this company are leeches..nothing more After all , another company in Boston , has a more polished , and brighter CEO with INSIDERS AS NET BUYERS OF THEIR HARD WORK AND VALUE THEY ARE CREATING . Here at AGIOS , NO EXECUTIVES BUY SHARES … THEY SELL THEIR GIFTED OPTIONS EVERY QUARTER and Morgan Stanley churns the stock higher for the losers , cause they can’t produce value on their watch !!! Read this and weep !!! CAN YOU SAY THE SAME FOR YOUR EXECUTIVE LOSERS !!! NEGATIVE !!!!

0 · Reply

Dkll303 May. 29 at 7:38 PM

$AGIO this pos company with their misfits running it, need a new CEO . A Michael Dell type, that gets things done . These clowns are on a huge tit of free money, produced by Chris Bowden , who left , but left them FCUK UP MONEY, AND THEY CLEARLY ARE PISSING IT AWAY MICHAEL …MICHAEL

0 · Reply

Agios Pharmaceuticals Transcript: Status update

Jun 1, 2026, 8:00 AM EDT - 3 days ago

Agios Pharmaceuticals Slides: Status update

Jun 1, 2026, 8:00 AM EDT - 3 days ago

Agios Pharmaceuticals Press release: Status update

2026-06-01T09:13:35.000Z - 3 days ago

Agios Pharmaceuticals enters license pact with Oscotec to develop cevidoplenib

Jun 1, 2026, 5:00 AM EDT - 3 days ago

Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib

2026-05-29T15:28:43.000Z - 6 days ago

Agios Pharmaceuticals price target lowered to $40 from $41 at BofA

May 29, 2026, 7:21 AM EDT - 6 days ago

Agios scraps blood cancer drug program after study miss

2026-05-29T11:08:17.000Z - 6 days ago

Agios will not advance tebapivat in lower-risk myelodysplastic syndromes

May 29, 2026, 7:00 AM EDT - 6 days ago

Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes

2026-05-22T14:25:48.000Z - 13 days ago

Agios announces EC grants marketing authorization for PYRUKYND

May 22, 2026, 10:18 AM EDT - 13 days ago

Avanzanite Bioscience's Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia

May 22, 2026, 9:15 AM EDT - 13 days ago

Agios' PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia

May 19, 2026, 11:00 AM EDT - 16 days ago

Agios Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

2026-05-12T19:25:15.000Z - 23 days ago

Agios Pharma submits sNDA to FDA for U.S. accelerated approval of mitapivat

2026-05-12T19:15:22.000Z - 23 days ago

Agios Pharmaceuticals to present mitapivat data at EHA Congress

May 12, 2026, 9:31 AM EDT - 23 days ago

Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease

May 12, 2026, 9:30 AM EDT - 23 days ago

Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias

2026-04-30T12:15:00.000Z - 5 weeks ago

Agios Pharmaceuticals price target lowered to $36 from $39 at Truist

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

Agios Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

Agios Pharmaceuticals Earnings release: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

Agios Pharmaceuticals Slides: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

Agios Pharmaceuticals Quarterly report: Q1 2026

2026-04-29T11:02:17.000Z - 5 weeks ago

Agios Pharmaceuticals reports Q1 EPS ($1.69), consensus ($1.79)

Apr 29, 2026, 6:30 AM EDT - 5 weeks ago

Agios Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 24, 2026, 8:00 AM EDT - 5 weeks ago

Agios Pharmaceuticals Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 5 weeks ago

Agios Pharmaceuticals Proxy statement: Proxy filing

2026-04-21T12:54:10.000Z - 6 weeks ago

Agios Pharmaceuticals price target lowered to $41 from $44 at BofA

NVO

2026-04-20T16:11:17.000Z - 6 weeks ago

H.C. Wainwright cuts Agios target on smaller market post Novo data

NVO

2026-04-20T16:00:43.000Z - 6 weeks ago

Agios Pharmaceuticals falls -23.4%

2026-04-20T15:09:57.000Z - 6 weeks ago

Agios Pharmaceuticals falls -23.7%

2026-04-20T14:34:15.000Z - 6 weeks ago

Agios sinks after Novo Nordisk reports sickle cell data

NVO

2026-04-06T12:31:27.000Z - 2 months ago

Agios Pharmaceuticals price target raised to $36 from $31 at JPMorgan

2026-04-06T12:26:47.000Z - 2 months ago

Agios Pharmaceuticals price target raised to $36 from $31 at JPMorgan

Apr 6, 2026, 7:00 AM EDT - 2 months ago

Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET

2026-04-01T10:27:47.000Z - 2 months ago

Agios Pharmaceuticals price target raised to $32 from $28 at Goldman Sachs

2026-03-31T17:30:41.000Z - 2 months ago

Leerink says Agios’ filing reinforces FDA flexibility ahead of Fulcrum update

FULC

Mar 31, 2026, 8:45 AM EDT - 2 months ago

PK Activation Gains Momentum in Thalassemia Agios' Aqvesme Launch Reflects Strong Promise with Deliberate Uptake

Mar 31, 2026, 7:00 AM EDT - 2 months ago

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

Mar 2, 2026, 11:50 AM EST - 3 months ago